Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
Authors
Keywords
-
Journal
Alzheimers & Dementia
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-12-01
DOI
10.1002/alz.12510
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
- (2021) Pratishtha Chatterjee et al. Translational Psychiatry
- Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
- (2021) Adam M. Brickman et al. Alzheimers & Dementia
- The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
- (2021) Oskar Hansson et al. Alzheimers & Dementia
- A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
- (2021) Tim West et al. Molecular Neurodegeneration
- Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
- (2021) Elisabeth H. Thijssen et al. Scientific Reports
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
- (2020) Shorena Janelidze et al. NATURE MEDICINE
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
- (2020) Elisabeth H. Thijssen et al. NATURE MEDICINE
- Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
- (2020) Thomas K Karikari et al. LANCET NEUROLOGY
- First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
- (2020) Sébastien Boulo et al. Alzheimers & Dementia
- Effect of Times to Blood Processing on the Stability of Blood Proteins Associated with Dementia
- (2020) Jui-Feng Chang et al. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
- (2020) Sebastian Palmqvist et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study
- (2020) Kumar B. Rajan et al. ANNALS OF NEUROLOGY
- Plasma Amyloid-β Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease
- (2020) Yen Ying Lim et al. JOURNAL OF ALZHEIMERS DISEASE
- Pre-Analytical Sampling and Storage Conditions of Amyloid-β Peptides in Venous and Capillary Blood
- (2020) Marlena Walter et al. JOURNAL OF ALZHEIMERS DISEASE
- Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
- (2020) Inge M. W. Verberk et al. Alzheimers Research & Therapy
- Serum neurofilament light chain withstands delayed freezing and repeated thawing
- (2020) Patrick Altmann et al. Scientific Reports
- Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
- (2020) Steffi De Meyer et al. Alzheimers Research & Therapy
- Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment
- (2019) Patrick Oeckl et al. JOURNAL OF ALZHEIMERS DISEASE
- Towards a unified protocol for handling of CSF before β-amyloid measurements
- (2019) Shorena Janelidze et al. Alzheimers Research & Therapy
- Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
- (2019) Kaj Blennow et al. Scientific Reports
- The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
- (2018) Oskar Hansson et al. Alzheimers & Dementia
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- High performance plasma amyloid-β biomarkers for Alzheimer’s disease
- (2018) Akinori Nakamura et al. NATURE
- Plasma amyloid as pre-screener for the earliest Alzheimer's pathological changes
- (2018) Inge M.W. Verberk et al. ANNALS OF NEUROLOGY
- Neurofilaments as biomarkers in neurological disorders
- (2018) Michael Khalil et al. Nature Reviews Neurology
- Serum GFAP as a biomarker for disease severity in multiple sclerosis
- (2018) A. Abdelhak et al. Scientific Reports
- Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
- (2018) Piotr Lewczuk et al. Alzheimers Research & Therapy
- Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
- (2018) Leslie M. Shaw et al. Alzheimers & Dementia
- Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42
- (2017) Seong Soo A. An et al. Alzheimers Research & Therapy
- Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
- (2017) Niklas Mattsson et al. JAMA Neurology
- Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma
- (2016) Virginia Pérez-Grijalba et al. JOURNAL OF ALZHEIMERS DISEASE
- Plasma tau in Alzheimer disease
- (2016) Niklas Mattsson et al. NEUROLOGY
- Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research
- (2015) Sid E. O'Bryant et al. Alzheimers & Dementia
- A Practical Guide to Immunoassay Method Validation
- (2015) Ulf Andreasson et al. Frontiers in Neurology
- Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
- (2014) Stephanie J. B. Vos et al. PLoS One
- CSF biomarker variability in the Alzheimer's Association quality control program
- (2013) Niklas Mattsson et al. Alzheimers & Dementia
- Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update
- (2012) Marta del Campo et al. Biomarkers in Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started